Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2016

View Archived Issues

NYMC and Interprotein collaborate on C2 domain-interactive therapeutics

Theranexus obtains funding for development of THN-201

Bayer and Evotec establish 5-year research partnership in kidney disease

Regen BioPharma's NR2F6 modulators show positive preclinical results

Abilita Bio awarded grant from NCI

Takeda and Affilogic establish Nanofitins research collaboration for neurological disorders

NuSirt and OWL Metabolomics partner to develop companion diagnostic for NS-0200

Chromosome 1 variant is associated with increased risk of IFN-beta-induced liver injury

NIH award supports Symbiotix's development of PSA for IBD

Novel model for the development of phages that target pathogenic bacteria

Artios Pharma launched to focus on developing novel DNA damage response cancer therapies

Allergan acquires Akarna Therapeutics

AstraZeneca withdraws MAA for cediranib

Aurigene Discovery Technologies patents PD-1 signaling inhibitors

Sunshine Lake Pharma discloses HCV inhibitors

Eleven Biotherapeutics acquires Viventia Bio

Nanjing Sanhome Pharmaceutical describes PI3Kdelta inhibitors

Medshine Discovery develops CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Melinta Therapeutics presents antibacterials

Quest Diagnostics launches Zika antibody test service

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Newron re-submits Xadago NDA

Regulus begins phase II trial of RG-012 in Alport syndrome

Takeda presents phase II results for TAK-448 in men with T2D and HH

Kadmon initiates phase II trials of KD-025 in psoriasis and GvHD

FDA approves Janssen Pharmaceuticals' Invokamet XR

Gilead stops phase II/III study of GS-5745 in ulcerative colitis based on DMC review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.